omeprazole has been researched along with Acute Coronary Syndrome in 15 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 9.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Omeprazole, usually used in the antiplatelet therapy during percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS), has been reported to increase ischemic events in retrospective studies." | 9.15 | Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. ( Chen, JS; Chen, L; Chen, YD; Guo, YS; Huang, TT; Liu, HB; Ren, YH; Sun, ZJ; Wang, CY; Wang, Y; Xie, YJ; Zhao, M, 2011) |
| "The aim of this study was to explore the individual effects of the CYP2C19 G681A polymorphism and omeprazole use and their interaction on clopidogrel responsiveness in acute coronary syndrome (ACS)." | 7.96 | Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome. ( Jirungda, S; Komanasin, N; Leuangwatthananon, W; Pussadhamma, B; Senthong, V, 2020) |
| "To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS)." | 7.80 | [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. ( Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H, 2014) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 5.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Omeprazole, usually used in the antiplatelet therapy during percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS), has been reported to increase ischemic events in retrospective studies." | 5.15 | Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. ( Chen, JS; Chen, L; Chen, YD; Guo, YS; Huang, TT; Liu, HB; Ren, YH; Sun, ZJ; Wang, CY; Wang, Y; Xie, YJ; Zhao, M, 2011) |
| "This study sought to compare the effect of 2 proton pump inhibitors (PPIs) on platelet response to clopidogrel after coronary stenting for non-ST-segment elevation acute coronary syndrome (NSTE ACS)." | 5.14 | Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Brissy, O; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "Dual antiplatelet therapy with aspirin and clopidogrel reduces cardiovascular events following an acute coronary syndrome or stent implantation, but the associated increased risk of gastro-intestinal bleeding often leads to the co-administration of proton pump inhibitors (PPIs)." | 4.90 | Proton pump inhibitors and clopidogrel: an association to avoid? ( D'Ugo, E; De Caterina, R; Rossi, S, 2014) |
| "To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS)." | 3.80 | [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. ( Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H, 2014) |
| "We conducted a retrospective cohort study to assess CV outcomes of 9753 patients taking dual antiplatelet therapy of aspirin plus clopidogrel with or without a PPI after hospitalization for acute coronary syndrome (ACS)." | 3.77 | Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. ( Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jirungda, S | 1 |
| Pussadhamma, B | 1 |
| Komanasin, N | 1 |
| Senthong, V | 1 |
| Leuangwatthananon, W | 1 |
| D'Ugo, E | 1 |
| Rossi, S | 1 |
| De Caterina, R | 1 |
| Juurlink, D | 1 |
| Amariles, P | 1 |
| Holguín, H | 1 |
| Angulo, NY | 1 |
| Betancourth, PM | 1 |
| Ceballos, M | 1 |
| Ford, NF | 1 |
| Vaduganathan, M | 1 |
| Cannon, CP | 1 |
| Cryer, BL | 1 |
| Liu, Y | 1 |
| Hsieh, WH | 1 |
| Doros, G | 1 |
| Cohen, M | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Bhatt, DL | 1 |
| Cuisset, T | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Poyet, R | 1 |
| Gaborit, B | 1 |
| Bali, L | 1 |
| Brissy, O | 1 |
| Morange, PE | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 1 |
| Juhász, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Vassiliou, V | 1 |
| Ren, YH | 1 |
| Zhao, M | 1 |
| Chen, YD | 1 |
| Chen, L | 1 |
| Liu, HB | 1 |
| Wang, Y | 1 |
| Sun, ZJ | 1 |
| Chen, JS | 1 |
| Huang, TT | 1 |
| Guo, YS | 1 |
| Xie, YJ | 1 |
| Wang, CY | 1 |
| Hsiao, FY | 1 |
| Mullins, CD | 1 |
| Wen, YW | 1 |
| Huang, WF | 1 |
| Chen, PF | 1 |
| Tsai, YW | 1 |
| Harrison, RW | 1 |
| Mahaffey, KW | 1 |
| Yano, H | 1 |
| Tsukahara, K | 1 |
| Morita, S | 1 |
| Endo, T | 1 |
| Sugano, T | 1 |
| Hibi, K | 1 |
| Himeno, H | 1 |
| Fukui, K | 1 |
| Umemura, S | 1 |
| Kimura, K | 1 |
| Horiuchi, H | 1 |
| Barada, K | 1 |
| Karrowni, W | 1 |
| Abdallah, M | 1 |
| Shamseddeen, W | 1 |
| Sharara, AI | 1 |
| Dakik, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for omeprazole and Acute Coronary Syndrome
| Article | Year |
|---|---|
Proton pump inhibitors and clopidogrel: an association to avoid?
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Lansopraz | 2014 |
Clopidogrel and Genotyping.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Gastroint | 2015 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
Clopidogrel and PPI interaction: clinically relevant or not?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; | 2012 |
4 trials available for omeprazole and Acute Coronary Syndrome
| Article | Year |
|---|---|
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Gastr | 2016 |
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Corona | 2009 |
Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; | 2011 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antago | 2012 |
7 other studies available for omeprazole and Acute Coronary Syndrome
| Article | Year |
|---|---|
Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cross-Sectional Studies; Cytochrome P-450 CYP2C19; Drug | 2020 |
Clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Clinical Trials as Topic; Clopidog | 2014 |
[Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Drug Interactio | 2014 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clop | 2011 |
Proton-pump inhibitors could be innocent when used concomitantly with clopidogrel.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Famotidine; Femal | 2012 |
Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Female; Fibrinolytic Agents; | 2008 |